Get informed when a big investor buys or sells
+ Follow51.96%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Novo Nordisk A/S (NOV.DE) currently reports a ROE of 51.96%. That is above the Healthcare sector average of 13.1%. Use the charts on this page to explore Novo Nordisk A/S's ROE history and peer comparisons.
Novo Nordisk A/S's ROE of 51.96% is higher than the Healthcare sector average of 13.1%. That is roughly 296.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Novo Nordisk A/S's current 51.96% should be judged against Healthcare norms (sector average: 13.1%) and against NOV.DE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 51.96%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for Novo Nordisk A/S, and consider following NOV.DE for alerts when major investors trade the stock.
Novo Nordisk A/S is classified in the Healthcare sector. On ROE, it currently shows 51.96% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NOV.DE with unrelated industries.